Company profile: Phathom Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical development focused on vonoprazan, a potassium-competitive acid blocker under clinical study for acid-related gastrointestinal disorders, including GERD and H. pylori. Activities include the pHalcon-NERD Phase 2 on-demand and Phase 3 daily dosing trials for NERD, and an Expanded Access Policy (no products currently available through this program).
Products and services
- Vonoprazan: A PCAB-class agent under clinical study engineered to block gastric acid for treating GERD and H. pylori infection across acid-related gastrointestinal disorders
- PHalcon-NERD Phase 3 Daily Dosing trial: A Phase 3 clinical study architected to assess the daily dosing regimen of vonoprazan for non-erosive gastroesophageal reflux disease (NERD)
- PHalcon-NERD Phase 2 On-demand trial: A Phase 2 clinical trial engineered to evaluate the efficacy and safety of on-demand vonoprazan for treating non-erosive gastroesophageal reflux disease (NERD)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phathom Pharmaceuticals
Edgewise Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of small-molecule therapies, including EDG-5506 to protect muscle fibers in rare skeletal muscle disorders (Duchenne and Becker muscular dystrophies), and EDG-7500, an oral, selective cardiac sarcomere modulator for hypertrophic cardiomyopathy and other diseases of cardiac diastolic dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Edgewise Therapeutics company profile →
Stealth Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapies targeting mitochondrial dysfunction, developing elamipretide to improve mitochondrial function for dry AMD, primary mitochondrial myopathy, Duchenne muscular dystrophy, and Barth syndrome, and SBT-272 for neurodegenerative diseases; conducts NuPOWER, TAZPOWER, and ReCLAIM-2 trials and offers an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stealth Biotherapeutics company profile →
Ultragenyx
HQ: United States
Website
- Description: Provider of therapeutics for rare and ultra-rare diseases, including CRYSVITA for XLH, MEPSEVII for MPS VII, and DOJOLVI for LC-FAOD. Develops investigational therapies such as UX143 (setrusumab) for osteogenesis imperfecta and GTX-102 for Angelman syndrome. Offers UltraCare patient support with assistance for insurance coverage, financial support, and access to resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultragenyx company profile →
Retrotope
HQ: United States
Website
- Description: Provider of a drug platform to preserve and restore mitochondrial health in degenerative diseases, developing isotopically stabilized fatty acid therapeutics to control metabolic processes linked to oxidative stress. Products include RT001, a clinical-stage isotopically stabilized synthetic linoleic acid for INAD, FA, ALS, and PSP, and RT011, an isotopically stabilized synthetic DHA advancing towards clinical trials for dry AMD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retrotope company profile →
Glycomine
HQ: United States
Website
- Description: Provider of replacement therapies for rare diseases, including GLM101, a mannose-1-phosphate replacement therapy in clinical development for PMM2-CDG that delivers mannose-1-phosphate directly into cells to bypass PMM2 enzyme deficiency, and a Natural History Study, a longitudinal study to understand PMM2-CDG symptoms, progression, and clinical measures and biomarkers for the disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycomine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phathom Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phathom Pharmaceuticals
2.2 - Growth funds investing in similar companies to Phathom Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phathom Pharmaceuticals
4.2 - Public trading comparable groups for Phathom Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →